Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma

  • Authors:
    • K Maeda
    • Y Chung
    • T Sawada
    • Y Ogawa
    • N Onoda
    • B Nakata
    • Y Kato
    • M Sowa
  • View Affiliations

  • Published online on: March 1, 1996     https://doi.org/10.3892/ijo.8.3.499
  • Pages: 499-503
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Urokinase-type plasminogen activator (UPA) is a serine protease implicated in cancer invasion and metastasis. There are at least two kinds of specific inhibitor which act on UPA: plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2). It has been reported that both UPA and PAI-1 antigen levels are associated with short survival in patients with breast cancer. In this study, we investigated the correlation between the expression of UPA, PAI-2 and prognosis in gastric carcinoma. One hundred and twenty specimens resected from patients with gastric carcinoma were investigated by staining with monoclonal antibodies against UPA and PAI-2. UPA positive rate was significantly higher in patients with liver metastases than in those without such metastases, There was no significant association between PAI-2 expression and clinicopathologic factors. However, patients with UPA-positive and PAI-2-negative tumors had more advanced cancer than other patients. According to the prognosis, the patients with UPA-positive and PAI-2-negative tumors had a significantly poorer prognosis than other patients. In conclusion, the combined evaluation of UPA and PAI-2 expression is associated with tumor progression in gastric cancer.

Related Articles

Journal Cover

March 1996
Volume 8 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Maeda, K., Chung, Y., Sawada, T., Ogawa, Y., Onoda, N., Nakata, B. ... Sowa, M. (1996). Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma. International Journal of Oncology, 8, 499-503. https://doi.org/10.3892/ijo.8.3.499
MLA
Maeda, K., Chung, Y., Sawada, T., Ogawa, Y., Onoda, N., Nakata, B., Kato, Y., Sowa, M."Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma". International Journal of Oncology 8.3 (1996): 499-503.
Chicago
Maeda, K., Chung, Y., Sawada, T., Ogawa, Y., Onoda, N., Nakata, B., Kato, Y., Sowa, M."Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma". International Journal of Oncology 8, no. 3 (1996): 499-503. https://doi.org/10.3892/ijo.8.3.499